Hepatitis C and Alternative Medicine News
http://feeds.blogsieve.com/677
Vancomycin-Resistant Enterococci (VRE) (MedicineNet Infectious Disease General)
Title: Vancomycin-Resistant Enterococci (VRE)
Category: Diseases and Conditions
Created: 5/8/2007
Last Editorial Review: 5/29/2008
Two Liver Cancer Treatments Better Than One (MedicineNet Hepatitis C Specialty)
Title: Two Liver Cancer Treatments Better Than One
Category: Health News
Created: 4/9/2008 2:00:00 AM
Last Editorial Review: 4/9/2008
The Digestive System (MedicineNet Hepatitis C Specialty)
Title: The Digestive System
Category: Diseases and Conditions
Created: 1/31/2005 8:20:00 AM
Last Editorial Review: 12/18/2007
Stool Color & Texture Changes (Black, Red, Maroon, Green, Yellow, Gray, Tarry, Sticky) ...
Title: Stool Color & Texture Changes (Black, Red, Maroon, Green, Yellow, Gray, Tarry, Sticky)
Category: Symptoms and Signs
Created: 4/17/2008
Last Editorial Review: 4/17/2008
Steno 'Superbug' Genome Shows Extreme Drug Resistance (MedicineNet Infectious Disease General)
Title: Steno 'Superbug' Genome Shows Extreme Drug Resistance
Category: Health News
Created: 5/10/2008 2:00:00 AM
Last Editorial Review: 5/12/2008
Silver-Coated Endotracheal Tubes Cut Down on Infections (MedicineNet Infectious Disease General)
Title: Silver-Coated Endotracheal Tubes Cut Down on Infections
Category: Health News
Created: 5/20/2008 2:00:00 AM
Last Editorial Review: 5/20/2008
Sharp Rise in U.S. Hepatitis C-Related Deaths (MedicineNet Hepatitis C Specialty)
Title: Sharp Rise in U.S. Hepatitis C-Related Deaths
Category: Health News
Created: 3/28/2008 2:00:00 AM
Last Editorial Review: 3/28/2008
Septic Arthritis (MedicineNet Hepatitis C Specialty)
Title: Septic Arthritis
Category: Diseases and Conditions
Created: 5/12/2008
Last Editorial Review: 5/12/2008
Scientists ID Enzyme That Allows Dysentery Amoeba to Hide (MedicineNet Infectious Disease General)
Title: Scientists ID Enzyme That Allows Dysentery Amoeba to Hide
Category: Health News
Created: 6/20/2008 2:00:00 AM
Last Editorial Review: 6/20/2008
Rheumatoid Arthritis Treatment Guidelines Updated (MedicineNet Hepatitis C Specialty)
Title: Rheumatoid Arthritis Treatment Guidelines Updated
Category: Health News
Created: 6/27/2008 2:00:00 AM
Last Editorial Review: 6/27/2008
MRSA Rates Tied to Hospital Understaffing (MedicineNet Infectious Disease General)
Title: MRSA Rates Tied to Hospital Understaffing
Category: Health News
Created: 6/25/2008 2:00:00 AM
Last Editorial Review: 6/25/2008
MRSA Infections Can Bug Fitness Buffs (MedicineNet Infectious Disease General)
Title: MRSA Infections Can Bug Fitness Buffs
Category: Health News
Created: 7/3/2008 2:00:00 AM
Last Editorial Review: 7/3/2008
Liver The Largest Gland in The Body (MedicineNet Hepatitis C Specialty)
Title: Liver The Largest Gland in The Body
Category: Doctor's Views
Created: 12/31/1997
Last Editorial Review: 3/3/2008
Hepatitis C: Nightmare in Vegas (MedicineNet Hepatitis C Specialty)
Title: Hepatitis C: Nightmare in Vegas
Category: Doctor's Views
Created: 3/4/2008
Last Editorial Review: 3/4/2008
Grapefruit Compound Inhibits Hepatitis C Virus (MedicineNet Hepatitis C Specialty)
Title: Grapefruit Compound Inhibits Hepatitis C Virus
Category: Health News
Created: 5/7/2008 2:00:00 AM
Last Editorial Review: 5/7/2008
Germicidal Wipes Can Spread Bacteria (MedicineNet Infectious Disease General)
Title: Germicidal Wipes Can Spread Bacteria
Category: Health News
Created: 6/4/2008
Last Editorial Review: 6/4/2008
Genetic Variation Doubles Risk of Liver Cancer (MedicineNet Hepatitis C Specialty)
Title: Genetic Variation Doubles Risk of Liver Cancer
Category: Health News
Created: 1/3/2008 2:00:00 AM
Last Editorial Review: 1/3/2008
Diabetes Boosts Liver Cancer Risk in Hepatitis, Cirrhosis Cases (MedicineNet Hepatitis C Specialty)
Title: Diabetes Boosts Liver Cancer Risk in Hepatitis, Cirrhosis Cases
Category: Health News
Created: 6/6/2008 2:00:00 AM
Last Editorial Review: 6/6/2008
Chronic Stomach Inflammation Boosts Cancer Risk (MedicineNet Hepatitis C Specialty)
Title: Chronic Stomach Inflammation Boosts Cancer Risk
Category: Health News
Created: 6/4/2008 2:00:00 AM
Last Editorial Review: 6/4/2008
C. diff Epidemic: What You Must Know (MedicineNet Infectious Disease General)
Title: C. diff Epidemic: What You Must Know
Category: Health News
Created: 6/2/2008
Last Editorial Review: 6/2/2008
Bug Off: Improved Repellents Beat DEET (MedicineNet Infectious Disease General)
Title: Bug Off: Improved Repellents Beat DEET
Category: Health News
Created: 5/28/2008
Last Editorial Review: 5/28/2008
Bug Bites and Stings (MedicineNet Infectious Disease General)
Title: Bug Bites and Stings
Category: Diseases and Conditions
Created: 6/19/2008
Last Editorial Review: 6/19/2008
Antibiotic Resistance (Drug Resistance, Antimicrobial Resistance) (MedicineNet Infectious ...
Title: Antibiotic Resistance (Drug Resistance, Antimicrobial Resistance)
Category: Diseases and Conditions
Created: 11/12/2004
Last Editorial Review: 5/29/2008
Abdominal Pain (MedicineNet Infectious Disease General)
Title: Abdominal Pain
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 7/1/2008
Expert Recap: Focus on Investigational HCV Agents (Clinical Care Options Hepatitis - HCV )
Ira M. Jacobson, MD, discusses the latest data on novel agents for the treatment of chronic hepatitis C.
Telaprevir Resistance Mutations Emerge Among Hepatitis C Patients Who Relapse Following ...
Telaprevir resistance mutations detected following 2 weeks of telaprevir-based therapy and standard peginterferon alfa-2a/ribavirin therapy
Significant Proportion of HCV/HIV-Coinfected Patients Refuse HCV Therapy in Large German ...
HCV/HIV-coinfected patients often decline anti-HCV therapy despite tolerability and efficacy of peginterferon alfa-2a plus ribavirin
Short Duration VCH-759 Demonstrates Potent Antiviral Activity in HCV Genotype 1a and 1b ...
Novel HCV NS5B polymerase inhibitor, VCH-759, shown to be safe and effective in genotype 1a and 1b patients during short-term study.
Robust Response to Peginterferon alfa-2b Plus Ribavirin Among HCV-Infected IV Drug Users on ...
HCV-infected IV drug users undergoing opioid maintenance therapy achieve response rates similar to patients not undergoing opioid therapy when adjusted for age, HCV genotype, and baseline HCV RNA level.
R7128, Promising Therapy for HCV Genotype 1 Nonresponders, Demonstrates Potent Antiviral ...
R7128 shown to be well tolerated with significant viral suppression and no viral rebound in HCV genotype 1-infected nonresponders over 14 days.
Peginterferon/Ribavirin/Nitazoxanide Increases Sustained Virologic Response Rate in ...
Study suggests potential SVR benefit to interferon-experienced patients with addition of nitazoxanide to standard-of-care peginterferon alfa-2a and ribavirin in genotype 4 HCV patients
PROVE2 Study Shows High SVR Rates With Combination Treatment With Telaprevir, Peginterferon ...
Telaprevir in combination with peginterferon alfa-2a plus ribavirin demonstrates strong virologic suppression with minimal adverse events.
PROVE 1 Study: Combination Telaprevir, Peginterferon alfa-2a, and Ribavirin Therapy Has Rapid ...
Telaprevir in combination with peginterferon alfa-2a and ribavirin results in high SVR rates treatment-naive HCV genotype 1 patients but is associated with increased incidence of dermatologic and gastrointestinal adverse events.
Multiple Infusions of Bavituximab Safe and Active Against HCV (Clinical Care Options ...
Bavituximab administered twice weekly for 2 weeks in HCV patients appears safe and well tolerated at doses up to 6 mg/kg
HCV Polymerase Inhibitor R1626 Has High Genetic Barrier to Resistance With Potent Antiviral ...
R1626 with or without peginterferon alfa-2a and ribavirin potently suppresses viral replication in patients chronically infected with HCV genotype 1
HCV Polymerase Inhibitor R1626 Combined With PegIFN/RBV Results in greater than 80% of HCV ...
High dosages of R1626 produce robust antiviral effects but are associated with high rates of cytopenias and gastrointestinal adverse events in HCV genotype 1 patients.
HCV FibroSURE and FIBROSpect II Comparable for Fibrosis Staging in Chronic Hepatitis C ...
Serodiagnostic marker panel tests FibroSURE and FIBROSpect II have similar positive and negative predictive abilities for staging METAVIR F2-F4 fibrosis.
GI-5005, a Yeast-Based Immunotherapy, Results in Dose-Dependent HCV-Specific Cellular Immune ...
Novel immunotherapy, GI-5005, results strong immune response, and some antiviral activity in chronic hepatitis C patients.
Favorable HCV, HBV Outcomes in HCV/HBV-Coinfected Patients Treated With Peginterferon alfa-2a ...
Peginterferon alfa-2a plus ribavirin therapy resulted in similar rates of HCV clearance when compared with HCV-monoinfected patients and led to HBsAg clearance in a significant proportion of patients at end-of-treatment follow-up
Expert Analysis: Update on Investigational Agents in HCV: 2007 (Clinical Care Options ...
Nezam H. Afdhal, MD, FRCPI, Ira M. Jacobson, MD, and David R. Nelson, MD review data from the meeting in Boston.
Exper Recap: Update on Investigational Agents in HCV: 2007 (Clinical Care Options Hepatitis - ...
Watch and listen as Ira M. Jacobson, MD, reviews key data on investigational HCV agents presented at the 2007 Boston liver disease meeting.
Development of Model for End-Stage Liver Disease Improved Graft and Overall Survival Rates ...
3-year graft and survival rates following liver transplant in HCC patients with and without HCV infection improved after development of MELD
Case: Management of a 38-Year-Old Male on Methadone Maintenance Therapy Who Presents With PCP ...
William G. Powderly, MD, discusses selection of initial therapy for a 38-year-old recovering IDU male with HIV/HCV coinfection who presents with PCP.
Biweekly Administration of Controlled-Release Recombinant Interferon alfa-2b Appears to Be ...
Phase IIa study of controlled-release recombinant interferon alfa-2b demonstrates potent antiviral activity and is well tolerated among HCV genotype 1-infected, treatment-naive patients
Albinterferon alfa-2b Achieves SVR in Some Hepatitis C Patients Who Failed Previous ...
Significant antiviral activity of higher doses of albinterferon alfa-2b in previous interferon/ribavirin HCV nonresponders may not translate into higher SVR rates.
Advances in HCV Management Strategies With Approved Agents (Clinical Care Options Hepatitis - ...
Raymond T. Chung, MD, Mitchell L. Shiffman, MD, and Mark S. Sulkowski, MD review new data from the meeting in Boston.
28 Days of Telaprevir, Peginterferon alfa-2a, and Ribavirin Followed by 44 Weeks of ...
Telaprevir shown to be safe and effective during combination treatment with peginterferon alfa-2a plus ribavirin among a small cohort of mostly minority patients.